Bufexamac | CP-1044-J-3 | Droxaryl | CAS#2438-72-4 | Non-Steroidal Anti-Inflammatory

MedKoo Cat#: 329211 | Name: Bufexamac

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bufexamac, also known as Droxaryl and CP-1044-J-3, is a benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. Bufexamac is used to treat various skin disorders.

Chemical Structure

Bufexamac

CAS#2438-72-4

Theoretical Analysis

MedKoo Cat#: 329211

Name: Bufexamac

CAS#: 2438-72-4

Chemical Formula: C12H17NO3

Exact Mass: 223.1208

Molecular Weight: 223.27

Elemental Analysis: C, 64.55; H, 7.67; N, 6.27; O, 21.50

Price and Availability

Size	Price	Availability
1g	USD 150.00	2 Weeks
2g	USD 250.00	2 Weeks
5g	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Bufexamac; CP-1044-J-3; CP 1044 J 3; CP1044J3; Droxaryl; Parfenac

IUPAC/Chemical Name

2-(4-butoxyphenyl)-N-hydroxyacetamide

InChi Key

MXJWRABVEGLYDG-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)

SMILES Code

O=C(NO)CC1=CC=C(OCCCC)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 223.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Pan Y, Nixon R. Allergic contact dermatitis to topical preparations of bufexamac. Australas J Dermatol. 2012 Aug;53(3):207-10. doi: 10.1111/j.1440-0960.2012.00876.x. PubMed PMID: 22881467. 2: Seto Y, Ochi M, Igarashi N, Inoue R, Oishi A, Toida T, Yamada S, Onoue S. In vitro photobiochemical characterization of sulfobutylether-β-cyclodextrin formulation of bufexamac. J Pharm Biomed Anal. 2011 Jun 1;55(3):591-6. doi: 10.1016/j.jpba.2011.02.025. PubMed PMID: 21429689. 3: Nakada T, Matsuzawa Y. Allergic contact dermatitis syndrome from bufexamac for nursing infant. Dermatitis. 2012 Jul-Aug;23(4):185-6. doi: 10.1097/DER.0b013e318260d774. PubMed PMID: 22828265. 4: Waltermann K, Marsch WCh, Kreft B. [Bufexamac-induced pigmented purpuric eruption]. Hautarzt. 2009 May;60(5):424-7. doi: 10.1007/s00105-008-1656-2. German. PubMed PMID: 19093092. 5: Fukuda H, Sato Y, Usami N, Yokouchi Y, Mukai H. Contact dermatitis caused by bufexamac sparing the eruption of herpes zoster. J Dermatol. 2012 Apr;39(4):405-7. doi: 10.1111/j.1346-8138.2011.01261.x. PubMed PMID: 21950459. 6: Schnuch A, Gefeller O, Uter W. [A common and insidious side-effect: allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK)]. Dtsch Med Wochenschr. 2005 Dec 16;130(50):2881-6. German. PubMed PMID: 16342011. 7: Uter W, Schnuch A. EMA revokes marketing authorization for bufexamac. Contact Dermatitis. 2011 Apr;64(4):235-6. doi: 10.1111/j.1600-0536.2011.01883.x. PubMed PMID: 21392031. 8: Marttinen PH, Raulo SM, Suominen MM, Tulamo RM. Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac. J Vet Med A Physiol Pathol Clin Med. 2006 Aug;53(6):311-8. PubMed PMID: 16901276. 9: Xiao Q, Dong N, Yao X, Wu D, Lu Y, Mao F, Zhu J, Li J, Huang J, Chen A, Huang L, Wang X, Yang G, He G, Xu Y, Lu W. Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H. Sci Rep. 2016 Apr 29;6:25298. doi: 10.1038/srep25298. PubMed PMID: 27126280; PubMed Central PMCID: PMC4850449. 10: Trommer H, Plätzer M, Raith K, Wohlrab W, Podhaisky HP, Neubert RH. Examinations of the antioxidative properties of the topically administered drug bufexamac reveal new insights into its mechanism of action. J Pharm Pharmacol. 2003 Oct;55(10):1379-88. PubMed PMID: 14607020. 11: Belhadjali H, Ghannouchi N, Njim L, Mohamed M, Moussa A, Bayou F, Chakroun M, Zakhama A, Zili J. Acute generalized exanthematous pustulosis induced by bufexamac in an atopic girl. Contact Dermatitis. 2008 Apr;58(4):247-8. doi: 10.1111/j.1600-0536.2007.01271.x. PubMed PMID: 18353041. 12: Proske S, Uter W, Schnuch A, Hartschuh W. [Severe allergic contact dermatitis with generalized spread due to bufexamac presenting as the "baboon" syndrome]. Dtsch Med Wochenschr. 2003 Mar 14;128(11):545-7. German. PubMed PMID: 12635026. 13: Suominen MM, Tulamo RM, Anttila MO, Sankari SM, Király K, Lapveteläinen T, Helminen HJ. Effects of intra-articular injections of bufexamac suspension in healthy horses. Am J Vet Res. 2001 Oct;62(10):1629-35. PubMed PMID: 11592331. 14: Arikawa J, Okabe S, Kaneko T. Allergic contact dermatitis with spreading over extensive regions due to topical use of 5% bufexamac ointment. J Dermatol. 2004 Feb;31(2):136-8. PubMed PMID: 15160871. 15: Suominen MM, Tulamo RM, Puupponen LM, Sankari SM. Effects of intra-articular injections of bufexamac suspension on amphotericin B-induced aseptic arthritis in horses. Am J Vet Res. 1999 Dec;60(12):1467-73. PubMed PMID: 10622153.